Biosimilars

Although the biotech industry is a relatively new source of medical therapies – its first new drug approvals came in the early 1980s – it has recently become a major source of drug industry growth and innovation. New biological entities (NBEs) have a significantly higher likelihood of being a first-in-class or novel introduction compared with